{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:08:10Z","timestamp":1792818490406,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100015613","name":"Centre Hospitalier Universitaire de Lille","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00198-025-07664-1","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:09:29Z","timestamp":1757344169000},"page":"2115-2126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity"],"prefix":"10.1007","volume":"36","author":[{"given":"L\u00e9a","family":"Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mabilleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-8623","authenticated-orcid":false,"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"7664_CR1","unstructured":"World Heath Organization. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 3\/3\/25."},{"issue":"7","key":"7664_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41569-023-00847-5","volume":"20","author":"PL Valenzuela","year":"2023","unstructured":"Valenzuela PL, Carrera-Bastos P, Castillo-Garc\u00eda A, Lieberman DE, Santos-Lozano A, Lucia A (2023) Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol 20(7):475\u2013494","journal-title":"Nat Rev Cardiol"},{"key":"7664_CR3","doi-asserted-by":"crossref","unstructured":"Yuen MMA (2023) Health complications of obesity: 224 obesity-associated comorbidities from a mechanistic perspective. Gastroenterol Clin North Am 52(2):363\u2013380","DOI":"10.1016\/j.gtc.2023.03.006"},{"key":"7664_CR4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jama.2020.12567","volume":"324","author":"DE Arterburn","year":"2020","unstructured":"Arterburn DE, Telem DA, Kushner RF, Courcoulas AP (2020) Benefits and risks of bariatric surgery in adults: a review. JAMA 324:879\u2013887","journal-title":"JAMA"},{"key":"7664_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2024.0318","volume":"331","author":"AP Courcoulas","year":"2024","unstructured":"Courcoulas AP, Patti ME, Hu B, Arterburn DE, Simonson DC, Gourash WF et al (2024) Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA 331:654\u2013664","journal-title":"JAMA"},{"issue":"10382","key":"7664_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","volume":"401","author":"CM Perdomo","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G (2023) Contemporary medical, device, and surgical therapies for obesity in adults. Lancet 401(10382):1116\u20131130","journal-title":"Lancet"},{"issue":"1","key":"7664_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000500779","volume":"66","author":"M Papageorgiou","year":"2020","unstructured":"Papageorgiou M, Kerschan-Schindl K, Sathyapalan T, Pietschmann P (2020) Is weight loss harmful for skeletal health in obese older adults? Gerontology 66(1):2\u201314","journal-title":"Gerontology"},{"key":"7664_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s00223-020-00798-w","volume":"110","author":"J Paccou","year":"2022","unstructured":"Paccou J, Caiazzo R, Lespessailles E, Cortet B (2022) Bariatric surgery and osteoporosis. Calcif Tissue Int 110:576\u2013591","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"7664_CR9","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/jbmr.2564","volume":"30","author":"J Zibellini","year":"2015","unstructured":"Zibellini J, Seimon RV, Lee CM et al (2015) Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials. J Bone Miner Res 30(12):2168\u20132178","journal-title":"J Bone Miner Res"},{"issue":"3","key":"7664_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/jbm4.10048","volume":"2","author":"C Gagnon","year":"2018","unstructured":"Gagnon C, Schafer AL (2018) Bone Health After Bariatric Surgery. JBMR Plus 2(3):121\u2013133","journal-title":"JBMR Plus"},{"key":"7664_CR11","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1210\/jc.2018-01496","volume":"103","author":"KG Lindeman","year":"2018","unstructured":"Lindeman KG, Greenblatt LB, Rourke C et al (2018) Longitudinal 5-year evaluation of bone density and microarchitecture after Roux-en-Y gastric bypass surgery. J Clin Endocrinol Metab 103:4104\u20134112","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"7664_CR12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/jbmr.4012","volume":"35","author":"J Paccou","year":"2020","unstructured":"Paccou J, Martign\u00e8ne N, Lespessailles E et al (2020) Gastric Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French Population-Based Cohort Study. J Bone Miner Res 35(8):1415\u20131423","journal-title":"J Bone Miner Res"},{"issue":"2","key":"7664_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","volume":"114","author":"J Herrou","year":"2024","unstructured":"Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, Paccou J (2024) Narrative review of effects of Glucagon-Like Peptide-1 Receptor Agonists on bone health in people living with obesity. Calcif Tissue Int 114(2):86\u201397","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 2","key":"7664_CR14","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/S1262-3636(08)73397-4","volume":"34","author":"JF Gautier","year":"2008","unstructured":"Gautier JF, Choukem SP, Girard J (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34(Suppl 2):S65-72","journal-title":"Diabetes Metab"},{"issue":"3","key":"7664_CR15","doi-asserted-by":"publisher","first-page":"e167952","DOI":"10.1172\/JCI167952","volume":"133","author":"J Bass","year":"2023","unstructured":"Bass J, Tsch\u00f6p MH, Beutler LR (2023) Dual gut hormone receptor agonists for diabetes and obesity. J Clin Invest 133(3):e167952","journal-title":"J Clin Invest"},{"issue":"15","key":"7664_CR16","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"Kusminski CM, Perez-Tilve D, M\u00fcller TD, DiMarchi RD, Tsch\u00f6p MH, Scherer PE (2024) Transforming obesity: The advancement of multi-receptor drugs. Cell 187(15):3829\u20133853","journal-title":"Cell"},{"issue":"4","key":"7664_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1210\/endrev\/bnaf006","volume":"46","author":"MM Wolfe","year":"2025","unstructured":"Wolfe MM, Boylan MO, Chin WW (2025) Glucose-dependent insulinotropic polypeptide in incretin physiology: role in health and disease. Endocr Rev 46(4):479\u2013500. https:\/\/doi.org\/10.1210\/endrev\/bnaf006","journal-title":"Endocr Rev"},{"issue":"11","key":"7664_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"10278","key":"7664_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984","journal-title":"Lancet"},{"issue":"1","key":"7664_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jamacardio.2024.4657","volume":"10","author":"I Shi","year":"2025","unstructured":"Shi I, Khan SS, Yeh RW, Ho JE, Dahabreh IJ, Kazi DS (2025) Semaglutide Eligibility Across All Current Indications for US Adults. JAMA Cardiol 10(1):96\u201398","journal-title":"JAMA Cardiol"},{"issue":"2","key":"7664_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40259-024-00699-6","volume":"39","author":"N Haddy","year":"2025","unstructured":"Haddy N, Jourdain H, Desplas D, Bertrand M, Jabagi MJ, Rives-Lange C, Zureik M (2025) Use of semaglutide (Wegovy) in adults in France: A nationwide drug utilization study. BioDrugs 39(2):321\u2013332. https:\/\/doi.org\/10.1007\/s40259-024-00699-6","journal-title":"BioDrugs"},{"issue":"1","key":"7664_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14656566.2024.2436595","volume":"26","author":"M Hamza","year":"2025","unstructured":"Hamza M, Papamargaritis D, Davies MJ (2025) Tirzepatide for overweight and obesity management. Expert Opin Pharmacother 26(1):31\u201349","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"7664_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"key":"7664_CR24","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I (2025) SURMOUNT-1 investigators. tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 6 392(10):958\u2013971","DOI":"10.1056\/NEJMoa2410819"},{"key":"7664_CR25","doi-asserted-by":"crossref","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators (2023) Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med 389(10):877\u2013888","DOI":"10.1056\/NEJMoa2302392"},{"issue":"6","key":"7664_CR26","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP et al (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389(6):514\u2013526","journal-title":"N Engl J Med"},{"issue":"6","key":"7664_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","volume":"392","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ (2025) Discovery of GLP-1-Based Drugs for the Treatment of Obesity. N Engl J Med 392(6):612\u2013615","journal-title":"N Engl J Med"},{"issue":"10401","key":"7664_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402(10401):529\u2013544","journal-title":"Lancet"},{"key":"7664_CR29","first-page":"756","volume":"19","author":"M Papageorgiou","year":"2023","unstructured":"Papageorgiou M, Biver E (2023) Bone consequences of intentional weight loss in overweight or obese patients. Rev Med Suisse 19:756\u2013760","journal-title":"Rev Med Suisse"},{"key":"7664_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/jbmr.3905","volume":"35","author":"R Armamento-Villareal","year":"2020","unstructured":"Armamento-Villareal R, Aguirre L, Waters DL, Napoli N, Qualls C, Villareal DT (2020) Effect of aerobic or resistance exercise, or both, on bone mineral density and bone metabolism in obese older adults while dieting: a randomized controlled trial. J Bone Miner Res 35:430\u2013439","journal-title":"J Bone Miner Res"},{"key":"7664_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/13697137.2012.667975","volume":"15","author":"A Pines","year":"2012","unstructured":"Pines A (2012) Weight loss, weight regain and bone health. Climacteric 15:317\u2013319","journal-title":"Climacteric"},{"issue":"6","key":"7664_CR32","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1210\/jc.2007-1473","volume":"93","author":"DT Villareal","year":"2008","unstructured":"Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S (2008) Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endocrinol Metab 93(6):2181\u20132187","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"7664_CR33","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/jbmr.3214","volume":"32","author":"KC Johnson","year":"2017","unstructured":"Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP et al (2017) The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial. J Bone Miner Res 32(11):2278\u20132287","journal-title":"J Bone Miner Res"},{"key":"7664_CR34","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1210\/jc.2018-02084","volume":"104","author":"E Lespessailles","year":"2019","unstructured":"Lespessailles E, Paccou J, Javier RM et al (2019) GRIO Scientific Committee Obesity, bariatric surgery, and fractures. J Clin Endocrinol Metab 104:4756\u20134768","journal-title":"J Clin Endocrinol Metab"},{"key":"7664_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116236","volume":"154","author":"J Paccou","year":"2022","unstructured":"Paccou J, Tsourdi E, Meier C, Palermo A, Pepe J, Body JJ, Zillikens MC (2022) Bariatric surgery and skeletal health: a narrative review and position statement for management by the European Calcified Tissue Society (ECTS). Bone 154:116236","journal-title":"Bone"},{"issue":"3","key":"7664_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.soard.2021.12.004","volume":"18","author":"J Paccou","year":"2022","unstructured":"Paccou J, Thuillier D, Courtalin M, Pigny P, Labreuche J, Cortet B, Pattou F (2022) A comparison of changes in bone turnover markers after gastric bypass and sleeve gastrectomy, and their association with markers of interest. Surg Obes Relat Dis 18(3):373\u2013383","journal-title":"Surg Obes Relat Dis"},{"key":"7664_CR37","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/jbmr.3371","volume":"33","author":"AL Schafer","year":"2018","unstructured":"Schafer AL, Kazakia GJ, Vittinghoff E et al (2018) Effects of gastric bypass surgery on bone mass and microarchitecture occur early and particularly impact postmenopausal women: bone mass and microarchitecture after gastric bypass surgery. J Bone Miner Res 33:975\u2013986","journal-title":"J Bone Miner Res"},{"key":"7664_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-17-0014","volume":"176","author":"VV Shanbhogue","year":"2017","unstructured":"Shanbhogue VV, St\u00f8ving RK, Frederiksen KH et al (2017) Bone structural changes after gastric bypass surgery evaluated by HR-pQCT: a two-year longitudinal study. Eur J Endocrinol 176:685\u2013693","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"7664_CR39","doi-asserted-by":"publisher","first-page":"e207419","DOI":"10.1001\/jamanetworkopen.2020.7419","volume":"3","author":"SI Khalid","year":"2020","unstructured":"Khalid SI, Omotosho PA, Spagnoli A, Torquati A (2020) Association of Bariatric Surgery With Risk of Fracture in Patients With Severe Obesity. JAMA Netw Open 3(6):e207419","journal-title":"JAMA Netw Open"},{"issue":"5","key":"7664_CR40","doi-asserted-by":"publisher","first-page":"R119","DOI":"10.1530\/EJE-20-0548","volume":"183","author":"KM Beavers","year":"2020","unstructured":"Beavers KM, Greene KA, Yu EW (2020) Management of endocrine disease: bone complications of bariatric surgery: updates on sleeve gastrectomy, fractures, and interventions. Eur J Endocrinol 183(5):R119\u2013R132","journal-title":"Eur J Endocrinol"},{"key":"7664_CR41","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1210\/en.2007-1292","volume":"149","author":"C Yamada","year":"2008","unstructured":"Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574\u2013579","journal-title":"Endocrinology"},{"key":"7664_CR42","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Molck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U (2010) Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473\u20131486","journal-title":"Endocrinology"},{"key":"7664_CR43","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1210\/jc.2010-2318","volume":"96","author":"L Hegedus","year":"2001","unstructured":"Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH (2001) GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 96:853\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"7664_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/JOE-13-0146","volume":"219","author":"G Mabilleau","year":"2013","unstructured":"Mabilleau G, Mieczkowska A, Irwin N, Flatt PR, Chappard D (2013) Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor. J Endocrinol 219:59\u201368","journal-title":"J Endocrinol"},{"key":"7664_CR45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-014-2845-8","volume":"26","author":"A Mieczkowska","year":"2015","unstructured":"Mieczkowska A, Mansur S, Bouvard B, Flatt PR, Thorens B, Irwin N, Chappard D, Mabilleau G (2015) Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength. Osteoporos Int 26:209\u2013218","journal-title":"Osteoporos Int"},{"key":"7664_CR46","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1089\/dna.2018.4397","volume":"37","author":"L Gao","year":"2018","unstructured":"Gao L, Li SL, Li YK (2018) Liraglutide promotes the osteogenic differentiation in MC3T3-E1 cells via regulating the expression of Smad2\/3 through PI3K\/Akt and Wnt\/beta-catenin pathways. DNA Cell Biol 37:1031\u20131043","journal-title":"DNA Cell Biol"},{"key":"7664_CR47","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","volume":"360","author":"X Wu","year":"2017","unstructured":"Wu X, Li S, Xue P, Li Y (2017) Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase A (PKA) signaling pathways involving beta-catenin. Exp Cell Res 360:281\u2013291","journal-title":"Exp Cell Res"},{"key":"7664_CR48","first-page":"234","volume":"41","author":"X Wu","year":"2018","unstructured":"Wu X, Li S, Xue P, Li Y (2018) Liraglutide inhibits the apoptosis of MC3T3-E1 cells induced by serum deprivation through cAMP\/PKA\/beta-catenin and PI3K\/AKT\/GSK3beta signaling pathways. Mol Cells 41:234\u2013243","journal-title":"Mol Cells"},{"key":"7664_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.110921","volume":"515","author":"Y Li","year":"2020","unstructured":"Li Y, Fu H, Wang H, Luo S, Wang L, Chen J, Lu H (2020) GLP-1 promotes osteogenic differentiation of human ADSCs via the Wnt\/GSK-3beta\/beta-catenin pathway. Mol Cell Endocrinol 515:110921","journal-title":"Mol Cell Endocrinol"},{"key":"7664_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/jre.12607","volume":"54","author":"Y Pang","year":"2019","unstructured":"Pang Y, Yuan X, Guo J, Wang X, Yang M, Zhu J, Wang J (2019) The effect of liraglutide on the proliferation, migration, and osteogenic differentiation of human periodontal ligament cells. J Periodontal Res 54:106\u2013114","journal-title":"J Periodontal Res"},{"key":"7664_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.170974","volume":"163","author":"S Zhai","year":"2023","unstructured":"Zhai S, Liu C, Vimalraj S, Subramanian R, Abullais SS, Arora S, Saravanan S (2023) Glucagon-like peptide-1 receptor promotes osteoblast differentiation of dental pulp stem cells and bone formation in a zebrafish scale regeneration model. Peptides 163:170974","journal-title":"Peptides"},{"key":"7664_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdent.2020.103310","volume":"94","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yuan X, Wu Y, Pei M, Yang M, Wu X, Pang Y, Wang J (2020) Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo. J Dent 94:103310","journal-title":"J Dent"},{"key":"7664_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110523","volume":"130","author":"Z Li","year":"2020","unstructured":"Li Z, Li S, Wang N, Xue P, Li Y (2020) Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-kappaB and MAPK pathways via GLP-1R. Biomed Pharmacother 130:110523","journal-title":"Biomed Pharmacother"},{"key":"7664_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.regpep.2011.12.006","volume":"175","author":"LB Knudsen","year":"2012","unstructured":"Knudsen LB, Hastrup S, Underwood CR, Wulff BS, Fleckner J (2012) Functional importance of GLP-1 receptor species and expression levels in cell lines. Regul Pept 175:21\u201329","journal-title":"Regul Pept"},{"key":"7664_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132744","volume":"10","author":"N Lu","year":"2015","unstructured":"Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J (2015) Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE 10:e0132744","journal-title":"PLoS ONE"},{"key":"7664_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bcp.2019.03.024","volume":"164","author":"S Pal","year":"2019","unstructured":"Pal S, Maurya SK, Chattopadhyay S, Pal China S, Porwal K, Kulkarni C, Sanyal S, Sinha RA, Chattopadhyay N (2019) The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts. Biochem Pharmacol 164:34\u201344","journal-title":"Biochem Pharmacol"},{"key":"7664_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","volume":"81","author":"M Pereira","year":"2015","unstructured":"Pereira M, Jeyabalan J, Jorgensen CS, Hopkinson M, Al-Jazzar A, Roux JP, Chavassieux P, Orriss IR, Cleasby ME, Chenu C (2015) Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 81:459\u2013467","journal-title":"Bone"},{"issue":"3","key":"7664_CR58","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s00210-024-03378-z","volume":"398","author":"MHH Abo-Elenin","year":"2025","unstructured":"Abo-Elenin MHH, Kamel R, Nofal S, Ahmed AAE (2025) The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis. Naunyn Schmiedebergs Arch Pharmacol 398(3):2677\u20132693","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"7664_CR59","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40618-019-01034-5","volume":"42","author":"L Yang","year":"2019","unstructured":"Yang L, Yang J, Pan T, Zhong X (2019) Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. J Endocrinol Invest 42:1125\u20131131","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"7664_CR60","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","volume":"191","author":"J Paccou","year":"2024","unstructured":"Paccou J, Yavropoulou MP, Naciu AM, Chandran M, Messina OD, Rolvien T, Carey JJ, D\u2019oronzo S, Anastasilakis AD, Saag KG, Lems WF (2024) Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. Eur J Endocrinol 191(6):G1\u2013G17","journal-title":"Eur J Endocrinol"},{"key":"7664_CR61","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1002\/jcp.25033","volume":"230","author":"SA Mansur","year":"2015","unstructured":"Mansur SA, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N, Mabilleau G (2015) Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus. J Cell Physiol 230:3009\u20133018","journal-title":"J Cell Physiol"},{"key":"7664_CR62","doi-asserted-by":"publisher","first-page":"763646","DOI":"10.3389\/fendo.2021.763646","volume":"12","author":"J Yu","year":"2021","unstructured":"Yu J, Shi YC, Ping F, Li W, Zhang HB, He SL, Zhao Y, Xu LL, Li YX (2021) Liraglutide inhibits osteoclastogenesis and improves bone loss by downregulating Trem2 in female type 1 diabetic mice: findings from transcriptomics. Front Endocrinol (Lausanne) 12:763646","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7664_CR63","first-page":"142","volume":"21","author":"K Chen","year":"2021","unstructured":"Chen K, Wu R, Mo B, Yan X, Shen D, Chen M (2021) Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density. J Musculoskelet Neuronal Interact 21:142\u2013148","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"7664_CR64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12891-022-05396-5","volume":"23","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Liu P, Xiang Q, Liang J, Chen H, Zhang H, Yang L (2022) Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway. BMC Musculoskelet Disord 23:465","journal-title":"BMC Musculoskelet Disord"},{"key":"7664_CR65","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.12659\/MSM.906603","volume":"23","author":"J Li","year":"2017","unstructured":"Li J, Fu LZ, Liu L, Xie F, Dai RC (2017) Glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide alters bone marrow exosome-mediated miRNA signal pathways in ovariectomized rats with type 2 diabetes. Med Sci Monit 23:5410\u20135419","journal-title":"Med Sci Monit"},{"key":"7664_CR66","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/1753-0407.12282","volume":"7","author":"HX Sun","year":"2015","unstructured":"Sun HX, Lu N, Luo X, Zhao L, Liu JM (2015) Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats. J Diabetes 7:584\u2013588","journal-title":"J Diabetes"},{"key":"7664_CR67","first-page":"5077","volume":"15","author":"B Wen","year":"2018","unstructured":"Wen B, Zhao L, Zhao H, Wang X (2018) Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Exp Ther Med 15:5077\u20135083","journal-title":"Exp Ther Med"},{"key":"7664_CR68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00223-020-00720-4","volume":"107","author":"A Mieczkowska","year":"2020","unstructured":"Mieczkowska A, Millar P, Chappard D, Gault VA (2020) Mabilleau G dapagliflozin and liraglutide therapies rapidly enhanced bone material properties and matrix biomechanics at bone formation site in a type 2 diabetic mouse model. Calcif Tissue Int 107:281\u2013293","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"7664_CR69","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/ph17121655","volume":"17","author":"F Lv","year":"2024","unstructured":"Lv F, Cai X, Lin C, Yang W, Ji L (2024) Effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice. Pharmaceuticals (Basel) 17(12):1655","journal-title":"Pharmaceuticals (Basel)"},{"key":"7664_CR70","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00521.2024","author":"CC Picoli","year":"2025","unstructured":"Picoli CC, Tsibulnikov S, Ho M, Demambro V, Feng T, Eltahir M, Le PT, Chlebek C, Rosen CJ, Ryzhov S, Li Z (2025) Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice. Am J Physiol Endocrinol Metab. https:\/\/doi.org\/10.1152\/ajpendo.00521.2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"7664_CR71","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren JR, Hartmann B et al (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 100(8):2909\u20132917. https:\/\/doi.org\/10.1210\/jc.2015-1176","journal-title":"J Clin Endocrinol Metab"},{"key":"7664_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"Hygum K, Harsl\u00f8f T, J\u00f8rgensen NR, Rungby J, Pedersen SB, Langdahl BL (2020) Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 132:115197","journal-title":"Bone"},{"issue":"72","key":"7664_CR73","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","volume":"3","author":"MS Hansen","year":"2024","unstructured":"Hansen MS, W\u00f6lfel EM, Jeromdesella S, M\u00f8ller JK, Ejersted C, J\u00f8rgensen NR, Eastell R, Hansen SG, Frost M (2024) Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 3(72):102624","journal-title":"EClinicalMedicine"},{"issue":"6","key":"7664_CR74","doi-asserted-by":"publisher","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","volume":"7","author":"SBK Jensen","year":"2024","unstructured":"Jensen SBK, S\u00f8rensen V, Sandsdal RM, Lehmann EW, Lundgren JR, Juhl CR et al (2024) Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 7(6):e2416775","journal-title":"JAMA Netw Open"},{"issue":"3","key":"7664_CR75","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/1753-0407.12102","volume":"6","author":"G Mabilleau","year":"2014","unstructured":"Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 6(3):260\u2013266","journal-title":"J Diabetes"},{"issue":"12","key":"7664_CR76","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","volume":"29","author":"YS Zhang","year":"2018","unstructured":"Zhang YS, Weng WY, Xie BC et al (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 29(12):2639\u20132644","journal-title":"Osteoporos Int"},{"issue":"12","key":"7664_CR77","doi-asserted-by":"publisher","first-page":"735824","DOI":"10.3389\/fendo.2021.735824","volume":"14","author":"YS Zhang","year":"2021","unstructured":"Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC (2021) Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. Front Endocrinol (Lausanne) 14(12):735824","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"7664_CR78","doi-asserted-by":"publisher","first-page":"e3168","DOI":"10.1002\/dmrr.3168","volume":"35","author":"L Cheng","year":"2019","unstructured":"Cheng L, Hu Y, Li YY, Cao X, Bai N, Lu TT, Li GQ, Li N, Wang AN, Mao XM (2019) Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 35(7):e3168","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"7664_CR79","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41569-023-00970-3","volume":"21","author":"I Fern\u00e1ndez-Ruiz","year":"2024","unstructured":"Fern\u00e1ndez-Ruiz I (2024) SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes. Nat Rev Cardiol 21(2):69","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"7664_CR80","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/oby.24222","volume":"33","author":"RF Kushner","year":"2025","unstructured":"Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J et al (2025) Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity 33(3):452\u2013462","journal-title":"Obesity"},{"issue":"24","key":"7664_CR81","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"2","key":"7664_CR82","first-page":"e240210","volume":"264","author":"E Tufail","year":"2025","unstructured":"Tufail E, Sanyal S, Mithal A, Sanyal S, Chattopadhyay N (2025) The role of glucagon-like peptides in osteosarcopenia. J Endocrinol 264(2):e240210","journal-title":"J Endocrinol"},{"issue":"369","key":"7664_CR83","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","volume":"15","author":"RS McIntyre","year":"2025","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Rhee TG, Cao B, Teopiz KM, Wong S, Le GH, Ho R, Kwan ATH (2025) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae). J Affect Disord 15(369):922\u2013927","journal-title":"J Affect Disord"},{"issue":"8","key":"7664_CR84","doi-asserted-by":"publisher","first-page":"e2423385","DOI":"10.1001\/jamanetworkopen.2024.23385","volume":"7","author":"G Schoretsanitis","year":"2024","unstructured":"Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C (2024) Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. JAMA Netw Open 7(8):e2423385","journal-title":"JAMA Netw Open"},{"issue":"1","key":"7664_CR85","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-024-04112-8","volume":"88","author":"J Zhou","year":"2025","unstructured":"Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X (2025) Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine 88(1):80\u201390","journal-title":"Endocrine"},{"issue":"2","key":"7664_CR86","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/edm2.70038","volume":"8","author":"C Abi Zeid Daou","year":"2025","unstructured":"Abi Zeid Daou C, Aboul Hosn O, Ghzayel L, Mourad M (2025) Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database. Endocrinol Diabetes Metab 8(2):e70038","journal-title":"Endocrinol Diabetes Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07664-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07664-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07664-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T13:03:32Z","timestamp":1763384612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07664-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7664"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07664-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JP has received consulting fees from Kyowa Kirin, Eli Lilly, and Theramex; honoraria from Amgen, Besins, CDD, Kyowa Kirin, and Theramex; payment for expert testimony from UCB; and support for attending meetings from Kyowa Kirin and Theramex. GM and LK has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}